Ginkgo Bioworks Holdings, Inc.
DNA
$7.71
-$0.14-1.78%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -82.59M | -80.75M | -80.76M | -60.30M | -90.96M |
| Total Depreciation and Amortization | 8.60M | 8.96M | 168.00K | 20.49M | 10.62M |
| Total Amortization of Deferred Charges | 4.20M | 4.70M | 14.00M | -4.70M | 4.20M |
| Total Other Non-Cash Items | 37.28M | 43.00M | 21.20M | 26.97M | 31.47M |
| Change in Net Operating Assets | -14.18M | -23.59M | 13.78M | -22.71M | -6.85M |
| Cash from Operations | -46.69M | -47.68M | -31.61M | -40.25M | -51.52M |
| Capital Expenditure | -1.93M | -5.00K | 0.00 | -38.00K | -7.62M |
| Sale of Property, Plant, and Equipment | -- | 574.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 25.07M | 94.53M | -72.82M | -63.85M | -191.06M |
| Cash from Investing | 23.13M | 95.10M | -72.82M | -63.89M | -198.68M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -19.00K | -25.00K | -24.00K | -98.00K | -207.00K |
| Issuance of Common Stock | -- | 9.15M | 10.32M | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -985.00K | -355.00K | -- | -- |
| Cash from Financing | -19.00K | 8.14M | 9.94M | -98.00K | -207.00K |
| Foreign Exchange rate Adjustments | -129.00K | -152.00K | 93.00K | 186.00K | 74.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -23.70M | 55.41M | -94.39M | -104.05M | -250.34M |